Skip Navigation

DRUG RECORD

 

LETROZOLE

OVERVIEW
Letrozole

 

Introduction

Letrozole is a nonsteroidal inhibitor of aromatase which effectively blocks estrogen synthesis in postmenopausal women and is used as therapy of estrogen receptor positive breast cancer, usually after resection and after failure of tamoxifen.  Letrozole has been associated with a low rate of serum enzyme elevations during therapy and rare instances of clinically apparent liver injury.

 

Background

Letrozole (let' roe zole) is a nonsteroidal aromatase inhibitor that is widely used as therapy of breast cancer, usually after surgical resection.  Aromatase is the enzyme responsible for the conversion of testosterone to estrone (E1) and of androstenedione to estradiol (E2).  Highest levels of aromatase are found in the ovary and placenta, which are the major sources of estrogen in premenopausal women.  However, aromatase is also found in other tissues, such as liver, kidney, adrenals, brain, muscle and subcutaneous fat where it is also active in producing estrogens, although at low levels.  These tissues are the major source of estrogen in postmenopausal women.  Inhibitors of aromatase were developed to block the synthesis of estrogen in the peripheral tissues and, thus, as antiestrogen therapy of breast cancer in postmenopausal women.  Letrozole is a nonsteroidal, specific aromatase inhibitor which has little or no effect on adrenal glucocorticoid or mineralocorticoid synthesis.  Letrozole was approved for use in postmenopausal women with estrogen receptor positive breast cancer in the United States in 1997.  Current indications aew as adjuvant therapy in postmenopausal women with estrogen sensitive breast cancer, given in daily oral doses for up to five years.  Letrozole is also indicated as a first line treatment of estrogen receptor positive (or unknown), locally advanced or metastatic breast cancer in postmenopausal women.  Letrozole is available in 2.5 mg tablets in generic forms and under the brand name Femara.  The recommended dose is one tablet daily.  Common side effects include hot flashes, night sweats, fatigue, dizziness, headache, somnolence, abdominal discomfort, nausea, arthralgias, weight gain and rash.  Uncommon, but potentially severe side effects include decrease in bone mineral density, increases in serum cholesterol levels and embryo-fetal toxicity.

 

Hepatotoxicity

Serum enzymes are reported to be elevated in up to 1% of women treated with letrozole, but these elevations are usually mild, asymptomatic and self-limited, rarely requiring dose modification.  There have been few published instances of clinically apparent liver injury associated with long term letrozole therapy.  More frequent have been reports of cholestatic and hepatocellular liver injury associated with anastrozole and exemestane, typically arising after 1 to 4 months of therapy and presenting with jaundice.  While cases have been severe, recovery is usually prompt once the agent is stopped.  There have been no cases of severe jaundice, acute liver failure, chronic hepatitis or vanishing bile duct syndrome attributed to letrozole use.  Unlike tamoxifen, letrozole has not been associated with development of fatty liver disease, steatohepatitis or cirrhosis. 

 

Likelihood score: D (possible rare cause of clinically apparent liver injury). 

 

Mechanism of Injury

The mechanism by which letrozole might cause liver injury is not known.  Letrozole is metabolized in the liver by the cytochrome P450 system and is a strong inhibitor of CYP 2A6 and to a lesser extent CYP 2C19.  However, it has not been linked to clinically significant drug-drug interactions.  Liver injury from letrozole might arise as a result of a toxic or immunogenic metabolite.

 

Outcome and Management

Liver injury attributed to letrozole is usually mild and self-limited, typically a transient, asymptomatic elevation in serum enzymes.  Cases of acute liver failure have been reported in women on other aromatase inhibitors, but not specifically letrozole.  There is little evidence for cross sensitivity to liver injury between letrozole and tamoxifen or even among the various aromatase inhibitors (which have distinctly different chemical structures).

 

References on the safety and hepatotoxicity of letrozole are listed below as well as together with those on anastrozole and exemestane at the end of the overview section on aromatase inhibitors.

Drug Class:  Antineoplastic Agents, Antiestrogens, Aromatase Inhibitors

 

Other Drugs in the Subclass, Aromatase Inhibitors:  Anastrozole, Exemestane

 

Top of page


 

REPRESENTATIVE TRADE NAMES
Letrozole – Generic, Femara®

 

DRUG CLASS
Antineoplastic Agents

 

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

 

Top of page


DRUG CAS REGISTRY NUMBER MOLECULAR FORMULA STRUCTURE
Letrozole 112809-51-5 C17-H11-N5 Letrozole Chemical Structure

Top of page


REFERENCES
Letrozole

 

References updated: 25 July 2017

  1. Zimmerman HJ. Unconventional drugs. Miscellaneous drugs and diagnostic chemicals. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 731-4.  (Expert review of hepatotoxicity published in 1999, before the availability of letrozole and the aromatase inhibitors).

  2. Chitturi S, Farrell GC. Estrogen receptor antagonists.  Adverse effects of hormones and hormone antagonists on the liver. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 610-2.  (Review of hepatotoxicity of tamoxifen mentions that nonalcoholic fatty liver disease is the most common form of liver injury due to tamoxifen which has also been reported to cause peliosis hepatis, acute hepatitis, submassive hepatic necrosis and liver cancer; no discussion of the aromatase inhibitors).

  3. Moy B, Lee RJ, Smith M. Anti-estrogen therapy. Natural products in cancer chemotherapy. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1756-9.  (Textbook of pharmacology and therapeutics).

  4. Monnier A. Long-term efficacy and safety of letrozole for the adjuvant treatment of early breast cancer in postmenopausal women: a review. Ther Clin Risk Manag 2009; 5: 725-38. PubMed Citation  (Review of the long term efficacy and safety of letrozole; no mention of ALT changes or hepatotoxicity).

  5. Reuben A, Koch DG, Lee WM; Acute Liver Failure Study Group. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology 2010; 52: 2065-76. PubMed Citation  (Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury, but none were attributed to letrozole or other antiestrogens).

  6. Dellapasqua S, Colleoni M. Letrozole. Expert Opin Drug Metab Toxicol 2010; 6: 251-9. PubMed Citation  (Literature review on safety and efficacy of letrozole; no mention of ALT changes or hepatotoxicity).

  7. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010; 28: 509-18. PubMed Citation  (Meta analysis of trials comparing aromatase inhibitors to tamoxifen as adjuvant therapy of breast cancer in postmenopausal women; no discussion of hepatotoxicity or rates of ALT elevations).

  8. Aromatase inhibitors for adjuvant treatment of postmenopausal breast cancer. Med Lett Drugs Ther 2011 13; 53 (1366):47-8. PubMed Citation  (Concise review of the aromatase inhibitors and their role in therapy of breast cancer in postmenopausal women; no discussion of adverse events).

  9. Barnadas A, Estevez LG, Lluch-Hernandez A, Rodriguez-Lescure A, Rodriguez-Sanchez C, Sanchez-Rovira P. An overview of letrozole in postmenopausal women with hormone-responsive breast cancer. Adv Ther 2011; 28: 1045-58. PubMed Citation (Review of the literature on the role of letrozole in postmenopausal women with breast cancer; no discussion of ALT changes or hepatotoxicity).

  10. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, et al.; BIG 1-98 Collaborative Group; International Breast Cancer Study Group(IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011; 12: 1101-8. PubMed Citation  (Randomized controlled trial of primary therapy with tamoxifen vs letrozole in 8010 women with breast cancer with an average follow up of 8.1 years showed improved survival with letrozole; no discussion of adverse events, ALT elevations or hepatotoxicity).

  11. Tomao F, Spinelli G, Vici P, Pisanelli GC, Cascialli G, Frati L, Panici PB, Tomao S. Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther 2011; 11: 1253-63. PubMed Citation  (Review of efficacy and safety of aromatase inhibitors in early breast cancer; no discussion of hepatotoxicity or ALT elevations).

  12. Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al.; United States Drug Induced Liver Injury Network. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015; 148: 1340-52. PubMed Citation  (Among 899 cases of drug induced liver injury seen over a ten year period at 8 US medical centers, 7 were attributed to antiestrogens used in cancer chemotherapy including 4 to tamoxifen, 2 exemestane and 1 letrozole, but none to anastrozole).

  13. Hong N, Yoon HG, Seo DH, Park S, Kim SI, Sohn JH, Rhee Y. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. Eur J Cancer 2017; 82: 103-14. PubMed Citation  (In a retrospective cohort study of 328 Korean women with breast cancer receiving antiestrogen adjuvant therapy, fatty liver as detected by ultrasound arose in 13 per 100 patient years on tamoxifen versus 8 per 100 on aromatase inhibitors [anastrozole or letrozole], and those on tamoxifen were more likely to progress [42% vs 10%]).

Top of page


OTHER REFERENCE LINKS
Letrozole
  1. PubMed logoRecent References on Letrozole

  2. Clinical Trials logoTrials on Letrozole

Top of page